search
Back to results

Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Primary Purpose

Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Synovial Sarcoma

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
CAB-AXL-ADC
PD-1 inhibitor
Sponsored by
BioAtla, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Undifferentiated Pleomorphic Sarcoma focused on measuring late stage, stage 3, stage 4, cancer

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must have measurable disease.
  • Age ≥ 12 years (Phase 2)
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.

Exclusion Criteria:

  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3011 administration.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Sites / Locations

  • The University of Arizona Cancer CenterRecruiting
  • Children's Hospital Los AngelesRecruiting
  • USC Norris Comprehensive Cancer CenterRecruiting
  • Tower Hematology Oncology Medical GroupRecruiting
  • UCSF Medical Center - Cancer Immunotherapy Clinic (CIC)Recruiting
  • University of ColoradoRecruiting
  • Sarah Cannon Research Institute at Health OneRecruiting
  • Children's Research InstituteRecruiting
  • Moffitt Cancer CenterRecruiting
  • Northwestern UniversityRecruiting
  • Norton Cancer InstituteRecruiting
  • Massachusetts General HospitalRecruiting
  • Dana-Farber Cancer InstituteRecruiting
  • Comprehensive Cancer Center of Nevada
  • Roswell Park Cancer InstituteRecruiting
  • Columbia UniversityRecruiting
  • Memorial Sloan KetteringRecruiting
  • Duke Cancer InstituteRecruiting
  • Wake Forest Baptist HealthRecruiting
  • University Hospitals Seidman Cancer CenterRecruiting
  • Nationwide Children's HospitalRecruiting
  • Oregon Health & Science UniversityRecruiting
  • The Children's Hospital of PhiladelphiaRecruiting
  • Tennessee OncologyRecruiting
  • Vanderbilt Ingram Cancer CenterRecruiting
  • Mary Crowley Cancer ResearchRecruiting
  • MD Anderson Cancer CenterRecruiting
  • University of Utah - Huntsman Cancer InstituteRecruiting
  • Seattle Cancer Care AllianceRecruiting
  • Prince of Wales HospitalRecruiting
  • Queen Mary HospitalRecruiting
  • National Cheng Kung University HospitalRecruiting
  • Taipei Veterans General HospitalRecruiting
  • Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

BA3011

Combination Therapy

Arm Description

Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.

Phase 2: BA3011 in combination with PD-1 inhibitor.

Outcomes

Primary Outcome Measures

Phase 1: Safety Profile
Assess dose limiting toxicity as defined in the protocol
Phase 1: Safety Profile
Assess maximum tolerated dose as defined in the protocol
Phase 1 and 2: Safety Profile
Frequency and severity of AEs and/or SAEs
Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1

Secondary Outcome Measures

Phase 1: Pharmacokinetics
Plasma concentrations of ADC, total antibody and MMAE
Phase 1: Pharmacokinetics
Peak Plasma Concentration (Cmax)
Phase 1: Pharmacokinetics
Area under the plasma concentration versus time curve (AUC)
Phase 1: Overall response rate (ORR)
Proportion of patients who achieve a confirmed CR or PR
Phase 1: Immunogenicity
The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)
Phase 1 and 2: Duration of response (DOR)
Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first
Phase 1 and 2: Progression-free survival (PFS)
Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first
Phase 1 and 2: Best overall response (OR)
All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy
Phase 1 and 2: Disease control rate (DCR)
Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks
Phase 1 and 2: Time to response (TTR)
Time from the first dose of investigational product until the first documentation of OR
Phase 1 and 2: Overall survival (OS)
Time from the first dose of BA3011 treatment until death due to any cause
Phase 1 and 2: Tumor size
Percent change from baseline in tumor size

Full Information

First Posted
January 22, 2018
Last Updated
September 25, 2023
Sponsor
BioAtla, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03425279
Brief Title
Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Official Title
A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2018 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioAtla, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
Detailed Description
This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced solid tumors in Phase 1 and BA3011 alone and in combination with a PD-1 inhibitor in Phase 2. Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct 2019) and a dose expansion phase (still enrolling ACC patients only). Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12 and over.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Synovial Sarcoma, Osteosarcoma, Ewing Sarcoma
Keywords
late stage, stage 3, stage 4, cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BA3011
Arm Type
Experimental
Arm Description
Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.
Arm Title
Combination Therapy
Arm Type
Experimental
Arm Description
Phase 2: BA3011 in combination with PD-1 inhibitor.
Intervention Type
Biological
Intervention Name(s)
CAB-AXL-ADC
Intervention Description
Conditionally active biologic anti-AXL antibody drug conjugate
Intervention Type
Biological
Intervention Name(s)
PD-1 inhibitor
Intervention Description
PD-1 inhibitor
Primary Outcome Measure Information:
Title
Phase 1: Safety Profile
Description
Assess dose limiting toxicity as defined in the protocol
Time Frame
Up to 24 months
Title
Phase 1: Safety Profile
Description
Assess maximum tolerated dose as defined in the protocol
Time Frame
Up to 24 months
Title
Phase 1 and 2: Safety Profile
Description
Frequency and severity of AEs and/or SAEs
Time Frame
Up to 24 months
Title
Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1
Description
Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1
Time Frame
Up to 24 months
Secondary Outcome Measure Information:
Title
Phase 1: Pharmacokinetics
Description
Plasma concentrations of ADC, total antibody and MMAE
Time Frame
Up to 24 months
Title
Phase 1: Pharmacokinetics
Description
Peak Plasma Concentration (Cmax)
Time Frame
Up to 24 months
Title
Phase 1: Pharmacokinetics
Description
Area under the plasma concentration versus time curve (AUC)
Time Frame
Up to 24 months
Title
Phase 1: Overall response rate (ORR)
Description
Proportion of patients who achieve a confirmed CR or PR
Time Frame
Up to 24 months
Title
Phase 1: Immunogenicity
Description
The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)
Time Frame
Up to 24 months
Title
Phase 1 and 2: Duration of response (DOR)
Description
Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first
Time Frame
Up to 24 months
Title
Phase 1 and 2: Progression-free survival (PFS)
Description
Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first
Time Frame
Up to 24 months
Title
Phase 1 and 2: Best overall response (OR)
Description
All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy
Time Frame
Up to 24 months
Title
Phase 1 and 2: Disease control rate (DCR)
Description
Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks
Time Frame
Up to 24 months
Title
Phase 1 and 2: Time to response (TTR)
Description
Time from the first dose of investigational product until the first documentation of OR
Time Frame
Up to 24 months
Title
Phase 1 and 2: Overall survival (OS)
Description
Time from the first dose of BA3011 treatment until death due to any cause
Time Frame
Up to 24 months
Title
Phase 1 and 2: Tumor size
Description
Percent change from baseline in tumor size
Time Frame
Up to 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have measurable disease. Age ≥ 12 years (Phase 2) Adequate renal function Adequate liver function Adequate hematological function Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Life expectancy of at least three months. Exclusion Criteria: Patients must not have clinically significant cardiac disease. Patients must not have known non-controlled CNS metastasis. Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study. Patients must not have had major surgery within 4 weeks before first BA3011 administration. Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload. Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C. Patients must not be women who are pregnant or breast feeding.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BioAtla Medical Affairs
Phone
858-558-0708
Ext
3333
Email
medicalaffairs@bioatla.com
Facility Information:
Facility Name
The University of Arizona Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janet Huynh
Phone
520-694-1231
Email
jhhyuynh@arizona.edu
First Name & Middle Initial & Last Name & Degree
Megan Hodges
Phone
520-694-9058
Email
mhodges@arizona.edu
First Name & Middle Initial & Last Name & Degree
Pavani Chalasani, MD
Facility Name
Children's Hospital Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abrahm Levi
Phone
323-361-6686
Email
alevi@chla.usc.edu
First Name & Middle Initial & Last Name & Degree
Leo Mascarenhas, MD
Facility Name
USC Norris Comprehensive Cancer Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Lee
Phone
323-865-0455
Email
Cristina.Lee@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Jacob Thomas, MD
Facility Name
Tower Hematology Oncology Medical Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roland Menendez
Phone
310-231-2184
Email
rmenendez@theangelesclinic.org
First Name & Middle Initial & Last Name & Degree
Linda Ford, PA-C
Phone
310-285-7268
Email
Linda.ford@cshs.org
First Name & Middle Initial & Last Name & Degree
Omid Hamid, MD
Facility Name
UCSF Medical Center - Cancer Immunotherapy Clinic (CIC)
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lea Daran
Email
lea.daran@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Brian Schulte, MD
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haley Stewart
Email
haley.stewart@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Heather McCoy
Email
Heather.McCoy@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Breelyn Wilky, MD
Facility Name
Sarah Cannon Research Institute at Health One
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Hall
Phone
720-754-2659
Email
Susan.Hall3@sarahcannon.com
First Name & Middle Initial & Last Name & Degree
Gerald Falchook, MD
Facility Name
Children's Research Institute
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ann Liew
Phone
202-476-6755
Email
aliew@childrensnational.org
First Name & Middle Initial & Last Name & Degree
AeRang Kim, MD, PhD
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Milijana Ugrenovic-Petrovic
Email
Milijana.Ugrenovic-Petrovic@moffitt.org
First Name & Middle Initial & Last Name & Degree
Soha Riad
Email
Soha.Riad@moffitt.org
First Name & Middle Initial & Last Name & Degree
Mihaela Druta, MD
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hannah Knott
Email
hannah.knott@northwestern.edu
First Name & Middle Initial & Last Name & Degree
Seth Pollack, MD
Facility Name
Norton Cancer Institute
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kylee Fleig
Phone
502-629-3681
Email
Kylee.Fleig@nortonhealthcare.org
First Name & Middle Initial & Last Name & Degree
Jaspreet Grewal, MD
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristina Goodwin
Email
kgoodwin@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Gregory Cote
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire Kowalczyk
Phone
617-582-8349
Email
clairel_kowalczyk@dfci.harvard.edu
First Name & Middle Initial & Last Name & Degree
Suzanne George, MD
Facility Name
Comprehensive Cancer Center of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89169
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Roswell Park Cancer Institute
City
Buffalo
State/Province
New York
ZIP/Postal Code
14263
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ajay Gupta
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Swathi Balaji
Phone
212-304-5548
Email
sb4461@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Morgan Bryant
Phone
212-342-9004
Email
mb4695@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Matthew Ingham, MD
Facility Name
Memorial Sloan Kettering
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jae Cho
Phone
646-888-1392
Email
choj3@mskcc.org
First Name & Middle Initial & Last Name & Degree
Taylor Jordan
Phone
646-888-1392
Email
JordanT@mskcc.org
First Name & Middle Initial & Last Name & Degree
Bill M. Tap, MD
Facility Name
Duke Cancer Institute
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ethan Miller
Email
ethan.d.miller@duke.edu
First Name & Middle Initial & Last Name & Degree
Richard Riedel, MD
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley C Fansler, RN
Phone
336-713-3539
Email
arcarrol@wakehealth.edu
First Name & Middle Initial & Last Name & Degree
Paul Savage, MD
Facility Name
University Hospitals Seidman Cancer Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kyle Logue
Phone
216-286-1090
Email
Kyle.Logue@uhhospitals.org
First Name & Middle Initial & Last Name & Degree
Ankit Mangla, MD
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karina Woodling
Email
karina.woodling@nationwidechildrens.org
First Name & Middle Initial & Last Name & Degree
Bhuvana Setty, MD
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Newby
Email
newbye@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Brett Rodgers
Email
rodgerbr@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Lara Davis, MD
Facility Name
The Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cindy Rodriguez
Email
rodriguecs@chop.edu
First Name & Middle Initial & Last Name & Degree
Theodore Laetsch, MD
Facility Name
Tennessee Oncology
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott Miller
Email
Scott.Miller3@sarahcannon.com
First Name & Middle Initial & Last Name & Degree
Howard Burris, MD
Facility Name
Vanderbilt Ingram Cancer Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathy Taylor
Phone
615-875-0060
Email
kathy.l.taylor@vumc.org
First Name & Middle Initial & Last Name & Degree
Elizabeth Davis, MD
Facility Name
Mary Crowley Cancer Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Bondurant
Phone
972-566-3065
Email
JBondurant@MaryCrowley.org
First Name & Middle Initial & Last Name & Degree
James Strauss, MD
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jordi Rodon
Phone
713-792-8927
Email
JRodon@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Denisse T Velazquez
Phone
832-728-5851
Email
DVelazquez1@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Jordi Rodon, MD
Facility Name
University of Utah - Huntsman Cancer Institute
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Sharry
Phone
801-585-3453
Email
susan.sharry@hci.utah.edu
First Name & Middle Initial & Last Name & Degree
Ashley Leary
Phone
801-213-8429
Email
Ashley.leary@hci.utah.edu
First Name & Middle Initial & Last Name & Degree
Anna Chalmers, MD
Facility Name
Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roxanne Moore
Email
romoore@seattlecca.org
First Name & Middle Initial & Last Name & Degree
Elizabeth Loggers, MD
Facility Name
Prince of Wales Hospital
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ka Wah Chu
Email
wah@clo.cuhk.edu.hk
First Name & Middle Initial & Last Name & Degree
Herbert Loong, MD
Facility Name
Queen Mary Hospital
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Winnie Chan
Email
winc@hku.hk
First Name & Middle Initial & Last Name & Degree
Thomas Yau, MD
Facility Name
National Cheng Kung University Hospital
City
Tainan
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hsueh-Fang Hsieh
Email
chavanadior@gmail.com
First Name & Middle Initial & Last Name & Degree
Wu-Chou Su, MD
Facility Name
Taipei Veterans General Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ting-Fang Kung
Email
roxykung@gmail.com
First Name & Middle Initial & Last Name & Degree
Chueh-Chuan Yen, MD
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li-Ying Ou
Email
sherryou@hotmail.com
First Name & Middle Initial & Last Name & Degree
Wen-Cheng Chang, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

We'll reach out to this number within 24 hrs